Table 2. Efficacy outcomes measures stratified according to the PD-L1 expression levels.
| Trial | ORR (PD-L1 ≥50%), n | ORR (PD-L1 1–49%), n | ORR (PD-L1 <1%), n | PFS (PD-L1 ≥50%) HR (95% CI) | PFS (PD-L1 1–49%) HR (95% CI) | PFS (PD-L1 <1%) HR (95% CI) | OS (PDL1 ≥50%) HR (95% CI) | OS (PD-L1 1–49%) HR (95% CI) | OS (PD-L1<1%) HR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| KEYNOTE-024 | 69/154 vs. 42/151 | NA | NA | 0.50 (0.37–0.68) | NA | NA | 0.65 (0.50–0.86) | NA | NA |
| KEYNOTE-042 | 118/299 vs. 96/300 | NA | NA | 0.83 (0.69–1.00) | NA | NA | 0.70 (0.58–0.86) | 0.91 (0.77–1.11) | NA |
| IMPower-110 | 41/107 vs. 28/98 | NA | NA | 0.63 (0.45–0.88) | NA | NA | 0.59 (0.40–0.89) | NA | NA |
| CheckMate-227 Part 1 (N vs. CT) | 79/214 vs. 68/192 | NA | 67/177 vs. 43/186 | 0.75 (0.59–0.95) | NA | 0.73 (0.56–0.95) | 0.69 (0.73–1.01) | NA | 0.78 (0.60–1.02) |
| MYSTIC (D vs. CT) | NA | NA | NA | NA | NA | NA | 0.76 (0.55–1.04) | NA | 1.18 (0.86–1.62) |
| EMPOWER-Lung 1 | 111/283 vs. 57/280 | NA | NA | 0.54 (0.43–0.68) | NA | NA | 0.57 (0.42–0.77) | NA | NA |
| KEYNOTE-189 | 81/132 vs. 16/70 | 40/124 vs. 9/62 | 41/127 vs. 9/63 | 0.36 (0.26–0.51) | 0.51 (0.36–0.73) | 0.64 (0.47–0.89) | 0.59 (0.39–0.88) | 0.62 (0.42–0.92) | 0.52 (0.36–0.74) |
| KEYNOTE-407 | 44/73 vs. 24/73 | 51/103 vs. 43/104 | 60/95 vs. 40/99 | 0.37 (0.24–0.58) | 0.56 (0.39–0.80) | 0.68 (0.47–0.98) | 0.64 (0.37–1.10) | 0.57 (0.36–0.90) | 0.61 (0.38–0.98) |
| IMPower-150 (A+B+CT vs. B+CT) | NA | NA | NA | 0.39 (0.25–0.60) | 0.56 (0.41–0.77) | 0.77 (0.61–0.99) | 0.70 (0.43–1.13) | 0.80 (0.55–1.15) | 0.90 (0.71–1.14) |
| IMPower-130 | NA | NA | NA | 0.51 (0.34–0.77) | 0.61 (0.43–0.85) | 0.72 (0.56–0.91) | 0.84 (0.51–1.39) | 0.70 (0.45–1.08) | 0.81 (0.61–1.08) |
| IMPower-132 | 18/25 vs. 11/20 | 24/63 vs. 28/73 | 39/88 vs. 20/75 | 0.46 (0.22–0.96) | 0.80 (0.56–1.16) | 0.45 (0.31–0.64) | NA | NA | NA |
| IMPower-131 | 19/32 vs. 5/16 | 35/67 vs. 23/53 | 31/70 vs. 30/71 | 0.44 (0.27–0.71) | 0.70 (0.53–0.92) | 0.81 (0.64–1.03) | 0.48 (0.29–0.81) | 1.08 (0.81–1.45) | 0.87 (0.67–1.13) |
| CheckMate-227 Part 2 (N + CT vs. CT) | NA | NA | NA | NA | NA | NA | 0.67 (0.44–1.01) | 0.94 (0.75–1.18) | 0.76 (0.58–1.00) |
| CheckMate–9LA | 38/76 vs. 30/98 | 50/127 vs. 26/106 | 42/135 vs. 26/129 | 0.61 (0.42–0.89) | 0.69 (0.51–0.94) | 0.71 (0.53–0.94) | 0.66 (0.44–0.99) | 0.61 (0.44–0.84) | 0.62 (0.45–0.85) |
| CheckMate-227 Part 1 (N + I vs. CT) | 91/205 vs. 68/192 | NA | 51/187 vs. 43/186 | 0.62 (0.49–0.69) | NA | 0.75 (0.59–0.96) | 0.70 (0.55–0.90) | 0.94 (0.75–1.18) | 0.62 (0.48–0.78) |
| MYSTIC (D + T vs. CT) | NA | NA | NA | NA | NA | NA | 0.77 (0.55–1.06) | NA | 0.73 (0.51–1.04) |
ORR, overall response rate; PFS, progression-free survival; OS, overall survival; PD-L1, programmed death-ligand 1; n, number; HR, hazard ratio; CI, confidence interval; CT, platinum-based chemotherapy; N, nivolumab; D, durvalumab; A, atezolizumab; B, bevacizumab; I, ipilimumab; T, tremelimumab; NA, not available.